A study touted by President Donald Trump, Republicans and business lobbyists on hydroxychloroquine as a treatment for COVID-19 doesn’t pass muster with Dr. Anthony Fauci.
Fauci, the director of the National Institute of Allergy and Infectious Diseases who advises the White House on coronavirus, testified before a U.S. House subcommittee Friday.
The Federal Drug Administration (FDA) has pulled the emergency authorization of hydroxychloroquine as a COVID-19 treatment after numerous studies have shown severe health risks for some patients. This week, former FDA head Scott Gottlieb said, “We can definitively say hydroxychloroquine doesn’t work.”
Trump said he took the drug in May as a preventative measure against coronavirus has continued to tweet his support for the drug.
On Friday, U.S. Rep. Blaine Luetkemeyer (R-Mo.) asked Fauci about the Dearborn-based Henry Ford Health System study that showed positive impacts.
“That study is a flawed study, and I think anyone who examines it carefully is that it is not a randomized placebo-controlled trial,” Fauci said.
He said it was a non-controlled, retrospective cohort study that had “a number of issues,” most notably that those patients who took hydroxychloroquine were also using corticosteroids.
Luetkemeyer noted that the study was peer-reviewed.
“It doesn’t matter; you can peer-review something that’s a bad study. The fact is it is not a randomized placebo-controlled trial,” Fauci said. “The point that I think is important, because we all want to keep an open mind, any and all of the randomized placebo-controlled trials, which is the gold standard of determining if something is effective, none of them have shown any efficacy for hydroxychloroquine.”